Quest Diagnostics to Launch TriPath's Pap Test

In a new agreement announced by Quest Diagnostics, Inc. (Teterboro, NJ, USA), and Tripath Imaging, Inc. (Burlington, NC, USA), Quest Diagnostics will launch TriPath Imaging's liquid-based Pap test for cervical cancer screening to its physician customers.

Quest Diagnostics will use TriPath Imaging's i3 Series integrated products, including the SurePath test pack and the PrepStain slide processor, and is finalizing its evaluation of the FocalPoint slide profiler for use in its operations. Both companies have agreed to work together to educate physicians about the benefits of the SurePath technology. The agreement provides for Quest Diagnostics to receive an initial issuance of warrants for TriPath Imaging common stock and to earn additional incentive warrants by achieving certain milestones. Additional terms were not disclosed.

"We selected TriPath Imaging's products and technology after an extensive evaluation and validation process,” said Joyce G. Schwartz, M.D., vice president and chief laboratory officer of Quest Diagnostics. "We look forward to offering the SurePath liquid-based Pap test as an important alternative to women and their doctors for use in cervical cancer screening.”

TriPath Imaging develops, manufactures, markets and sells products designed to improve the clinical management of cancer, including detection, diagnosis, staging, and
treatment.



Related Links:
Quest Diagnostics
Tripath Imaging